Factors Associated with Increased Risk of Major Cardiovascular Events for Patients Undergoing CAR T Therapy.

Autor: Reves, H., Eljalby, M., Rao, A., Chandra, A., Zhang, K., Muquith, M., Jackson, M., Geethakumari, P. Ramakrishnan, Afrough, A., Anderson, L. D., Khan, A., Collins, R. H., Kaur, G., Madanat, Y. F., Wolfe, H. R., Yilmaz, E., Zaha, V. G., Awan, F. T.
Předmět:
Zdroj: Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p537-537, 1p
Abstrakt: B Introduction: b Chimeric antigen receptor (CAR)-T cell therapy use has increased exponentially following its approval for multiple indications in non-Hodgkin lymphomas, multiple myeloma, and acute lymphoblastic leukemia. Patients who experienced MACE versus no MACE had a significantly higher age at CAR-T cell therapy (74.5 years vs. 64.9 years, I p i =.009), higher peak C-reactive protein (CRP) with a median of 116.7 mg/dL versus 73.85 mg/dL, I p i = 0.006 respectively. [Extracted from the article]
Databáze: Complementary Index
Externí odkaz: